Next 10 |
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Hea...
2024-06-16 15:58:28 ET A recent rash of cyberattacks on Corporate America has put cybersecurity back in the spotlight.... Read the full article on Seeking Alpha For further details see: SA Asks: What is the No. 1 cybersecurity threat facing companies today?
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at h...
2024-06-04 12:48:12 ET Genetic database builder 23andMe (NASDAQ: ME) stock slid 10% through 12:05 p.m. ET Tuesday. Curiously, though, the news that 23andMe reported today seemed generally of the "good" variety. The company announced a collaboration with the nonprofit Colorectal ...
SUNNYVALE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, and the Colorectal Cancer Alliance (Alliance), the largest nonprofit organization dedicated to ending colorectal cancer, announced a collaborati...
– 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and tolerability, and achieves the prespecified targets for maximal pharmacology at ...
The LRRK2 variant is strongly associated with symptoms of Parkinson’s disease (PD) that are different from non-variant carriers with the disease The study revealed novel findings of genetic “hotspots” in people from Mexico, Cuba, Puerto Rico, and Brazil, where the founder...
2024-05-23 19:44:09 ET 23andMe Holding Co. (ME) Q4 2024 Earnings Conference Call May 24, 2024 4:30 PM ET Company Participants Ian Cooney - Senior Director of Investor Relations Joe Selsavage - Chief Financial Officer and Chief Accounting Officer Anne Wojcicki - C...
2024-05-23 16:42:20 ET More on 23andMe 23andMe CEO Anne Wojcicki eyes taking DNA-testing company private Seeking Alpha’s Quant Rating on 23andMe Historical earnings data for 23andMe Financial information for 23andMe Read the full article on S...
2024-05-23 16:12:10 ET More on 23andMe 23andMe CEO Anne Wojcicki eyes taking DNA-testing company private Seeking Alpha’s Quant Rating on 23andMe Historical earnings data for 23andMe Financial information for 23andMe Read the full article on S...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Hea...
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at h...
2024-06-04 12:48:12 ET Genetic database builder 23andMe (NASDAQ: ME) stock slid 10% through 12:05 p.m. ET Tuesday. Curiously, though, the news that 23andMe reported today seemed generally of the "good" variety. The company announced a collaboration with the nonprofit Colorectal ...